GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
A Study of Patients With HER2 Gene Amplified Metastatic Breast Cancer Treated With First Line Herceptin and a Taxane
Completed
- Conditions
- First Posted Date
- 2004-11-25
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1000
- Registration Number
- NCT00097487
An Observational Study of the Use and Safety of Raptiva During Pregnancy (FOLLOW)
- First Posted Date
- 2004-11-22
- Last Posted Date
- 2010-08-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT00097240
- Locations
- 🇺🇸
FOLLOW Raptiva Pregnancy Registry, Morrisville, North Carolina, United States
A Study to Evaluate Rituximab in Adults With Relapsing Remitting Multiple Sclerosis
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-11-19
- Last Posted Date
- 2014-03-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 104
- Registration Number
- NCT00097188
- Locations
- 🇺🇸
Michigan Institute For Neurological Disorders, Farmington Hills, Michigan, United States
🇺🇸Neurology and Neuroscience Assoc.,INC, Akron, Ohio, United States
🇺🇸MS Center of Vero Beach, Vero Beach, Florida, United States
A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
Phase 4
Completed
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00096980
A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT)
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2017-06-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 333
- Registration Number
- NCT00096954
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT00096967
A Study of Bevacizumab in Ovarian Cancer or Primary Peritoneal Cancer Where Doxil or Topotecan Therapy Has Failed
Phase 2
Completed
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2017-05-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT00097019
A Study to Evaluate Psoriasis Outcomes and Safety Events in Patients With Chronic Moderate to Severe Plaque Psoriasis (RESPONSE)
Completed
- Conditions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1846
- Registration Number
- NCT00096928
- Locations
- 🇺🇸
SunValley Arthritis Center Ltd, Glendale, Arizona, United States
🇺🇸George Washington University Medical Center, Washington, District of Columbia, United States
🇺🇸Dermatology and Advanced Aesthetics, Lake Charles, Louisiana, United States
A Study to Evaluate Subjects Treated With rhuMab 2C4 (Pertuzumab) in a Previous Genentech Phase II Cancer Study
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2015-06-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT00096941
A Study to Evaluate rhuMab 2C4 and Gemcitabine in Subjects With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2004-11-18
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 131
- Registration Number
- NCT00096993
- Locations
- 🇺🇸
Carle Clinic Association, Urbana, Illinois, United States
🇺🇸Franklin Square Hospital Center, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
© Copyright 2024. All Rights Reserved by MedPath